NCT07007208RecruitingPhase 2
Biomarkers of the Locus Coeruleus Nucleus: Links With Early Tau Pathology, Cognition and Alzheimer's Disease Risk
Biomarkers of the Locus Coeruleus Nucleus: Links With Early Tau Pathology, Cognition and Alzheimer's Disease Risk.
Source: ClinicalTrials.gov · Last updated 17 Jul 2026
Brief summary (registry, in English)
Alzheimer's disease (AD) is characterized by a long-lasting silent phase. Among initial events, emergence of tau pathology in locus coeruleus (LC) brainstem nucleus, well before the one observed in medial temporal cortex, is highly relevant. LC integrity and function can be assessed in vivo with MRI and pupil measures. The current research proposes to evaluate these LC markers in an aged healthy cohort (n=100, with half APOE4 positive) and to relate these markers with cerebral tau pathology, AD risk and cognitive function.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 12 May 2025
- Start date
- 2 Feb 2026
- Primary completion date
- 31 Jan 2029
- Lead sponsor
- University Hospital, Toulouse
- Diseases
- Alzheimer disease
- NCT number
- NCT07007208
- EU CT number
- 2023-507668-38-00
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 100
- From 2 Feb 2026 to the primary completion date, 31 Jan 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Subjects with a psychiatric disorder and a PHQ-9 score \> 10 or under treatment with NRI
Other illness
- Subjects with a known allergic reaction to the PET radiopharmaceutical (\[18F\] Flortaucipir) or any of its excipients
- Subjects with a neurodegenerative condition or a history of cerebral ischemia
Other
- Subjects with a contraindication to MRI exam
- Subjects with an ophthalmological pathology making oculometric measurements difficult
Who the study is looking for
- Participant in the INSPIRE-T cohort
- Normal cognitive assessment
- MMSE score ≥ 27 out of 30 (Mini-Mental State Examination)
- Normal visual abilities (in corrected or uncorrected vision)
- Normal motor skills
Age in the registry: 60 years to 100 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital of Toulouse Coordinator of this site? Confirm its status | Toulouse | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.